- Home
- LZB vs KROS Comparison
LZB vs KROS Comparison
Compare LZB & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LZB
- KROS
- Stock Information
- Founded
- LZB 1927
- KROS 2015
- Country
- LZB United States
- KROS United States
- Employees
- LZB N/A
- KROS N/A
- Industry
- LZB Home Furnishings
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- LZB Consumer Discretionary
- KROS Health Care
- Exchange
- LZB Nasdaq
- KROS Nasdaq
- Market Cap
- LZB 1.7B
- KROS 1.8B
- IPO Year
- LZB N/A
- KROS 2020
- Fundamental
- Price
- LZB $42.77
- KROS $56.62
- Analyst Decision
- LZB Hold
- KROS Strong Buy
- Analyst Count
- LZB 1
- KROS 8
- Target Price
- LZB N/A
- KROS $91.43
- AVG Volume (30 Days)
- LZB 385.4K
- KROS 383.1K
- Earning Date
- LZB 11-19-2024
- KROS 11-06-2024
- Dividend Yield
- LZB 1.87%
- KROS N/A
- EPS Growth
- LZB N/A
- KROS N/A
- EPS
- LZB 2.81
- KROS N/A
- Revenue
- LZB $2,060,908,000.00
- KROS $651,000.00
- Revenue This Year
- LZB $2.59
- KROS $1,232.45
- Revenue Next Year
- LZB $3.95
- KROS $126.39
- P/E Ratio
- LZB $15.22
- KROS N/A
- Revenue Growth
- LZB N/A
- KROS 8037.50
- 52 Week Low
- LZB $30.68
- KROS $27.31
- 52 Week High
- LZB $45.23
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- LZB 63.39
- KROS 38.94
- Support Level
- LZB $40.65
- KROS $65.54
- Resistance Level
- LZB $44.29
- KROS $70.26
- Average True Range (ATR)
- LZB 0.96
- KROS 3.17
- MACD
- LZB 0.47
- KROS -0.64
- Stochastic Oscillator
- LZB 75.68
- KROS 9.07
About LZB La-Z-Boy Incorporated
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; and Retail, which sells upholstered and case goods furniture to the end consumer. The majority of the company's revenue is derived from its Wholesale segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.